Stock listing
BOATS:SMMT Summit Therapeutics Inc. Stock
US listing (BOATS) of Summit Therapeutics Inc. · home listing NASDAQ:SMMT
Follow Summit Therapeutics Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SMMT
$15.83 USD -0.26 (-1.6%)
Close on Oct 21, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SMMT
- Day range
- $15.72 – $16.35 USDOct 21, 2026
- Volume
- 5.36M sharesOct 21, 2026
- Market cap
- $12.63B USDAt the close on Oct 21, 2026 · price × 797.7M shares outstanding
- 52-week range
- $12.07 – $29.23 USDLowest and highest trades, Oct 22, 2025 – Oct 21, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SMMT · Home | $15.83 USD | -0.26 (-1.6%) | 5,363,609 | $16.35 | $16.35 | $15.72 | $16.09 | Close on Oct 21, 2026 |
Daily closes
Last 3 months, Jul 21, 2026 – Oct 21, 2026 · NASDAQ:SMMT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $15.83 | -0.26 | -1.6% | $16.35 | $16.35 | $15.72 | 5,363,609 | |
| $16.09 | +0.52 | +3.3% | $15.50 | $16.18 | $15.06 | 6,224,409 | |
| $15.57 | +0.94 | +6.4% | $14.90 | $15.77 | $14.83 | 6,140,366 | |
| $14.63 | -0.74 | -4.8% | $15.39 | $15.41 | $14.56 | 4,316,200 | |
| $15.37 | +0.24 | +1.6% | $15.09 | $15.55 | $15.08 | 4,726,800 | |
| $15.13 | -0.39 | -2.5% | $15.29 | $15.57 | $15.04 | 4,657,100 | |
| $15.52 | -1.61 | -9.4% | $16.79 | $16.79 | $15.47 | 7,132,000 | |
| $17.13 | -0.46 | -2.6% | $17.48 | $17.59 | $17.05 | 4,371,200 | |
| $17.59 | +0.42 | +2.4% | $17.36 | $17.62 | $16.82 | 5,751,500 | |
| $17.17 | -0.78 | -4.3% | $17.61 | $17.64 | $16.80 | 6,173,200 | |
| $17.95 | +0.64 | +3.7% | $17.10 | $18.33 | $16.98 | 8,167,900 | |
| $17.31 | +0.04 | +0.2% | $17.49 | $17.53 | $16.53 | 5,872,900 | |
| $17.27 | +0.515 | +3.1% | $16.97 | $17.62 | $16.44 | 5,277,700 | |
| $16.76 | +0.065 | +0.4% | $16.96 | $17.32 | $16.66 | 5,190,100 | |
| $16.69 | -0.22 | -1.3% | $16.82 | $17.50 | $16.59 | 7,898,900 | |
| $16.91 | +0.52 | +3.2% | $16.59 | $17.72 | $16.17 | 13,060,400 | |
| $16.39 | +0.91 | +5.9% | $18.91 | $19.09 | $16.15 | 27,340,000 | |
| $15.48 | -0.13 | -0.8% | $15.50 | $15.82 | $15.18 | 6,151,100 | |
| $15.61 | -0.77 | -4.7% | $16.45 | $16.58 | $15.55 | 3,800,400 | |
| $16.38 | -0.07 | -0.4% | $16.37 | $16.78 | $16.09 | 5,044,600 | |
| $16.45 | -0.67 | -3.9% | $17.10 | $17.46 | $16.25 | 3,889,800 | |
| $17.12 | +0.22 | +1.3% | $16.97 | $17.50 | $16.79 | 4,617,200 | |
| $16.90 | -0.95 | -5.3% | $18.40 | $18.42 | $16.64 | 5,777,800 | |
| $17.85 | +0.13 | +0.7% | $17.74 | $17.87 | $17.31 | 13,059,500 | |
| $17.72 | +0.42 | +2.4% | $17.73 | $18.10 | $17.42 | 6,133,500 | |
| $17.30 | -0.10 | -0.6% | $17.50 | $17.75 | $17.11 | 6,087,500 | |
| $17.40 | -1.02 | -5.5% | $18.16 | $18.47 | $17.11 | 5,794,700 | |
| $18.42 | +0.87 | +5.0% | $18.07 | $18.83 | $17.97 | 7,059,000 | |
| $17.55 | +0.55 | +3.2% | $17.20 | $17.70 | $17.14 | 4,275,200 | |
| $17.00 | -0.54 | -3.1% | $17.30 | $17.62 | $16.80 | 4,220,400 | |
| $17.54 | +0.26 | +1.5% | $18.21 | $18.32 | $17.24 | 4,802,300 | |
| $17.28 | -0.325 | -1.8% | $17.43 | $17.69 | $16.97 | 7,353,200 | |
| $17.61 | +0.475 | +2.8% | $16.94 | $17.63 | $16.80 | 6,946,100 | |
| $17.13 | +2.53 | +17.3% | $15.52 | $17.35 | $15.52 | 14,922,200 | |
| $14.60 | +0.44 | +3.1% | $14.15 | $14.72 | $14.06 | 3,779,200 | |
| $14.16 | +0.54 | +4.0% | $13.38 | $14.48 | $13.37 | 4,701,900 | |
| $13.62 | -0.11 | -0.8% | $13.51 | $13.73 | $13.44 | 5,424,600 | |
| $13.73 | -0.60 | -4.2% | $14.11 | $14.24 | $13.43 | 3,905,300 | |
| $14.33 | +0.10 | +0.7% | $14.30 | $14.65 | $13.92 | 4,836,700 | |
| $14.23 | +0.87 | +6.5% | $14.75 | $15.10 | $14.11 | 11,625,800 | |
| $13.36 | +0.63 | +4.9% | $13.27 | $13.60 | $13.05 | 6,333,700 | |
| $12.73 | -0.43 | -3.3% | $13.08 | $13.21 | $12.22 | 4,389,300 | |
| $13.16 | +0.73 | +5.9% | $12.69 | $13.53 | $12.57 | 7,072,900 | |
| $12.43 | -0.68 | -5.2% | $13.01 | $13.02 | $12.29 | 6,568,700 | |
| $13.11 | +0.29 | +2.3% | $13.31 | $13.39 | $12.92 | 5,431,200 | |
| $12.82 | +0.04 | +0.3% | $12.60 | $13.00 | $12.53 | 4,603,900 | |
| $12.78 | -0.57 | -4.3% | $13.05 | $13.07 | $12.07 | 9,878,600 | |
| $13.35 | -0.65 | -4.6% | $13.61 | $13.71 | $12.99 | 9,748,900 | |
| $14.00 | -1.10 | -7.3% | $15.16 | $15.24 | $13.99 | 6,562,500 | |
| $15.10 | -0.015 | -0.1% | $15.41 | $15.75 | $15.00 | 3,676,400 | |
| $15.12 | +0.245 | +1.6% | $15.03 | $15.73 | $14.68 | 4,960,100 | |
| $14.87 | +0.91 | +6.5% | $14.14 | $14.90 | $14.10 | 3,491,600 | |
| $13.96 | +0.42 | +3.1% | $13.90 | $14.02 | $13.52 | 2,182,600 | |
| $13.54 | +0.01 | +0.1% | $13.63 | $13.93 | $13.44 | 2,487,300 | |
| $13.53 | -0.23 | -1.7% | $13.91 | $13.96 | $13.44 | 3,154,600 | |
| $13.76 | +0.715 | +5.5% | $13.20 | $13.98 | $13.11 | 3,999,900 | |
| $13.05 | +0.025 | +0.2% | $13.11 | $13.25 | $12.77 | 3,451,600 | |
| $13.02 | -0.42 | -3.1% | $13.44 | $13.59 | $13.01 | 3,995,100 | |
| $13.44 | +0.64 | +5.0% | $12.79 | $13.56 | $12.72 | 3,815,400 | |
| $12.80 | +0.25 | +2.0% | $12.61 | $13.24 | $12.30 | 3,777,900 | |
| $12.55 | -0.555 | -4.2% | $13.01 | $13.05 | $12.25 | 5,017,500 | |
| $13.11 | -0.555 | -4.1% | $13.85 | $14.23 | $13.10 | 4,231,500 | |
| $13.66 | -1.32 | -8.8% | $13.72 | $14.42 | $13.20 | 8,153,700 | |
| $14.98 | +0.24 | +1.6% | $14.73 | $15.23 | $14.58 | 3,283,500 | |
| $14.74 | +0.11 | +0.8% | $15.18 | $15.71 | $14.65 | 4,255,900 | |
| $14.63 | +1.13 | +8.4% | $13.67 | $14.72 | $13.63 | 3,925,500 |
- Ticker
- BOATS:SMMT
- Asset type
- Stock
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 21, 2026
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Latest earnings call · Jul 23, 2026
Summit Therapeutics (NASDAQ:SMMT) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Jul 23, 2026
Q2 2026 Earnings Presentation
Earnings · 15 slides
Calls
Replays
Summit Therapeutics (NASDAQ:SMMT) Q2 2026 Earnings Call
Thu, Jul 23, 2026 · 4:30 PM ET
Watch TranscriptSummit Therapeutics (NASDAQ:SMMT) Q4 2025 Earnings Call
Mon, Feb 23, 2026 · 4:30 PM ET
Watch TranscriptSummit Therapeutics (NASDAQ:SMMT) Q3 2025 Earnings Call
Mon, Oct 20, 2025 · 8:00 AM ET
Watch Transcript
Latest news
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Oct 21, 2026
Closed $15.83 (-1.6%) on Oct 21, 2026
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
Oct 19, 2026
Closed $15.57 (+6.4%) on Oct 19, 2026
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Oct 5, 2026
Closed $17.27 (+3.1%) on Oct 5, 2026
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Oct 2, 2026
Closed $16.76 (+0.4%) on Oct 2, 2026
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Oct 2, 2026
Closed $16.76 (+0.4%) on Oct 2, 2026
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Sep 28, 2026
Closed $16.39 (+5.9%) on Sep 29, 2026
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
Sep 22, 2026
Closed $17.12 (+1.3%) on Sep 22, 2026
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Sep 15, 2026
Closed $17.40 (-5.5%) on Sep 15, 2026
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Sep 13, 2026
Closed $18.42 (+5.0%) on Sep 14, 2026
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Aug 25, 2026
Closed $13.36 (+4.9%) on Aug 25, 2026
Financings
Strategic investment of convertible preferred stock
Oct 5, 2026
Closed: US$2B raised
Buyers: AstraZeneca (approximately 108,955 shares of convertible preferred stock for $2.0 billion)
Use of proceeds: Accelerated development of ivonescimab across solid tumor settings, including combinations with antibody drug conjugates
Decks
Q2 2026 Earnings Presentation
Earnings · 15 slides · Jul 23, 2026
ASCO 2026 Update Call
Conference · 18 slides · Jun 1, 2026
Q4 2025 Earnings Presentation
Earnings · 15 slides · Feb 23, 2026
44th Annual J.P. Morgan Healthcare Conference 2026
Conference · 15 slides · Jan 12, 2026
Summit Therapeutics Inc. on 6ix
- News releases
- 34 in the last 12 months · 158 in all · newest Oct 21, 2026 · oldest 2019
- Calls
- 11 calls with a replay · 11 with a transcript · latest Jul 23, 2026
- Decks
- 32 decks · latest Jul 23, 2026
Where Summit Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SMMT · Home listing | NASDAQ | United States | USD |
| BMV:SMMT | BMV | Mexico | MXN |
| BOATS:SMMT · This page | BOATS | United States | USD |
| BIVA:SMMT | BIVA | Mexico | MXN |
Log in to ask 6ix AI your own questions about Summit Therapeutics Inc.